NIH, Wellcome Trust Fund African Heredity and Health Project



By Bio-IT World Staff

June 23, 2010 | The Wellcome Trust and the National Institutes of Health have launched a $38 million partnership focused on Africa to study how genes and the environment, including diet, work together to affect cancer, heart disease, and other diseases.

The Human Heredity and Health in Africa Project (H3 Africa) will receive at least $12 million from the Wellcome Trust and $5 million a year from the NIH, along with administrative and scientific support, over the next five years. The NIH has provided $750 000 to kick-start the project.

Previous research suggests that there is greater genetic diversity in African populations than those in Europe and Asia. Researchers hope that the project will shed light on the way genes influence how individuals respond to infection and medications. Working with thousands people in Africa may unveil rare genetic variations and in turn open up new ways to diagnose disease and develop treatments.

The African Society for Human Genetics is helping to organize research groups. Key to the project will be building research capacity, including infrastructure and training in African countries such as Cameroon, Ghana, Mali, Sudan, Tanzania, and Tunisia. Two working groups, on communicable and non-communicable disease, have been set up to help guide the initiative. These will convene for a series of planning meetings at the University of Oxford in August and Cape Town, South Africa, in the autumn.

"In the past, many research projects simply took samples from Africa and conducted the studies back in Western labs," said Charles N Rotimi, President of the African Society and Director of the Center for Research on Genomics and Global Health at the National Human Genome Research Institute, in a press release.

"H3 Africa will build the capacity for African researchers to study African populations to solve African problems, and will create strong collaborations between African researchers and those in Europe, the United States, and other parts of the world."

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .